Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Isodiol International Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Camper8on Dec 24, 2018 9:46am
154 Views
Post# 29153600

NEWS!

NEWS! https://ceo.ca/@nasdaq/isodiol-international-inc-comments-on-us-farm-bill

The Company also wishes to announce the divesting of its Canadian assets.  The Company has sold its interest in Canadian National Pharma Group Inc. in exchange for a return of capital investment of CAD$900,000, which will be paid in installments over the next nine months. Over the course of this transaction, no stock was issued to CN Pharma.  The divestiture marks a strategy shift whereby the company intends to make its products available in Canada through manufacturing and distribution partnerships with existing Licensed Producers in multiple jurisdictions, rather than through a captive Licensed Dealer in British Columbia. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities